Recent clinical trial looked at THC in Alzheimer’s

  • SAFER, MORE EFFECTIVE
  • REDUCES AGITATION
  • HELPS PAIN AND WEIGHT GAIN
  • MAY PROTECT THE BRAIN
  • BETTER QUALITY OF LIFE FOR PATIENTS AND CAREGIVERS

May also protect the brain

A synthetic form of THC may be “a safer and more effective treatment” for Alzheimer’s-related aggression, anxiety, depression and psychosis, according to an article in Contemporary Clinical Trials Communications, also published in Science Direct.

The clinical trial found that Nabilone may also have benefits for weight and pain.” it said.

“Nabilone…may provide a safer and more effective treatment for agitation, while potentially having benefits for weight and pain.”

The authors also said that nabilone could potentially protect the brain, as well.

Caregiver relief

Patients with moderate-to-severe Alzheimer’s could have a better quality-of-life, while also reducing stress on caregivers.

And better treatment also helps avoid the costs of long-term care in institutions, they said.

Groundwork for bigger clinical trial

The study aimed to lay the groundwork for a large, multi-centre trial using the synthetic cannabinoid nabilone.

The randomized, double-blind, placebo-controlled clinical trial began in 2015 and was completed in April 2019.

It was sponsored by Sunnybrook Research Institute in Toronto, Ontario, Canada.